The estimated Net Worth of Jeffrey Nau is at least $5.28 Millón dollars as of 21 October 2021. Jeffrey Nau owns over 50,000 units of Oyster Point Pharma Inc stock worth over $1,238,731 and over the last 5 years he sold OYST stock worth over $0. In addition, he makes $4,037,700 as President, Chief Executive Officer y Director at Oyster Point Pharma Inc.
Jeffrey has made over 6 trades of the Oyster Point Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of OYST stock worth $51,000 on 21 October 2021.
The largest trade he's ever made was exercising 50,000 units of Oyster Point Pharma Inc stock on 21 October 2021 worth over $51,000. On average, Jeffrey trades about 7,167 units every 60 days since 2019. As of 21 October 2021 he still owns at least 110,898 units of Oyster Point Pharma Inc stock.
You can see the complete history of Jeffrey Nau stock trades at the bottom of the page.
Dr. Jeffrey Nau Ph.D. serves as President, Chief Executive Officer, Director of the Company. Previously, Dr. Nau was Vice President of Clinical and Medical Affairs at Ophthotech Corporation, a clinical-stage biopharmaceuticals company, from July 2013 to March 2017. Currently, he is a member of the Board of Directors for BioNJ. Prior to Ophthotech, he was a Medical Science Director at Genentech, a biotechnology company, from October 2011 to July 2013. From September 2006 to October 2011, Dr. Nau was Vice President of Medical and Clinical Affairs at NeoVista. Dr. Nau received a B.S. in Biology from Stony Brook University, an M.S. in medical science from Drexel University College of Medicine, and a Ph.D. in public health and epidemiology from Walden University. Nau is qualified to serve on our board of directors because of the perspective and experience he provides as our President and Chief Executive Officer as well as his broad experience within the life sciences industry.
As the President, Chief Executive Officer y Director of Oyster Point Pharma Inc, the total compensation of Jeffrey Nau at Oyster Point Pharma Inc is $4,037,700. There are no executives at Oyster Point Pharma Inc getting paid more.
Jeffrey's mailing address filed with the SEC is C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 106, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver... y Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Oyster Point Pharma Inc executives and other stock owners filed with the SEC include: